EMA finds lack of evidence on pancreatic risks with GLP-1s

Current evidence does not show that glucagon-like peptide-1 agonists increase the risk of pancreatitis and pancreatic-duct metaplasia in patients with type 2 diabetes, the European Medicines Agency's Committee for Medicinal Products for Human Use indicated. "However, the number of events is too small to draw final conclusions. Due to their mechanism of action, some uncertainties remain in respect to the long-term effect of these medicines on the pancreas, and more data collection efforts are under way," the agency stated.

View Full Article in:

Healio · New York Times (tiered subscription model), The · PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX